Constructive Bio secures $58m in Series A funding to advance synthetic genomics technology.
The Series A round was led by Ahren, OMX Ventures, and Paladin Capital Group to develop biomanufacturing platforms.
≈ £43.3M at $1 = £0.7457 on 26 Sep 2024
Constructive Bio is a synthetic genomics startup that rewrites genomes to build novel biomolecules and sustainable materials. The company originated as a spinout from the University of Cambridge.
Constructive Bio has raised $58m in the first close of its Series A financing round to advance its synthetic genomics technology. The investment was led by Ahren, OMX Ventures, and Paladin Capital Group, with participation from Fine Structure Ventures, +ND Capital, and Jonathan Milner. The company will use the capital to further develop its platform for creating new biomolecules and therapeutics.
Founded in 2022 as a spinout from the University of Cambridge, the firm turns living cells into biofactories for sustainable materials and pharmaceuticals. Sir Gregory Winter has joined the board as an Ahren representative as part of the transaction.
From the founder
"Synthetic genomics is redefining how we harness biology. Our suite of proprietary technologies and incomparable team allows us to build novel materials and products that will revolutionise drug manufacturing and discovery,"
Ola Wlodek
CEO at Constructive Bio
Investor perspective
"Constructive Bio has cutting-edge technology with exceptional near- and long-term potential. It couples groundbreaking innovation with multiple distinct routes to market, and is set to revolutionise the sustainable biomanufacturing of new products across industries."
Shyam Kamadolli
Managing Director, Fine Structure Ventures
Use of funds
- 01Continue product development
Investors
Sir Winter
Ahren
OMX Ventures
Paul Conley
Paladin Capital
Shyam Kamadolli
Fine Structure Ventures
+ND Capital
Jonathan Milner
About the company
Constructive Bio
Constructive Bio rewrites genomes to turn living cells into sustainable biofactories.